SCHEMBL27000489

CC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)C[C@H]1OP(=O)(S)OC[C@H]1O[C@@H](n2cc(C)c(=O)[nH]c2=O)C[C@H]1OP(=O)(S)OC[C@H]1O[C@@H](n2cc(C)c(=O)[nH]c2=O)C[C@H]1OP(=O)(S)OC[C@H]1O[C@@H](n2cnc3c(=O)[nH]c(N)nc32)C[C@H]1OP(=O)(S)OC[C@H]1O[C@@H](n2cnc3c(=O)[nH]c(N)nc32)C[C@H]1OP(=O)(S)OC[C@H]1O[C@@H](n2cc(C)c(=O)[nH]c2=O)C[C@H]1OP(=O)(S)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)C[C@H]1OP(=O)(S)OC

nearest known ligand 0.55

Predicted protein targets (top 9)

	gene	UniProt	supporting neighbours	confidence
▸	TERT	O14746	2/20	0.55

▸	DTYMK	P23919	4/20	0.53

▸	F2	P00734	2/20	0.52

▸	POLB	P06746	1/20	0.45

▸	TK1	P04183	1/20	0.42

▸	P2RY2	P41231	1/20	0.42

▸	P2RY4	P51582	1/20	0.42

▸	P2RY6	Q15077	1/20	0.42

▸	STING1	Q86WV6	2/20	0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL25580372	1.00	TERT (0.55)	TERTDTYMKF2POLBTK1
SCHEMBL26860402	1.00	TERT (0.55)	TERTDTYMKF2POLBTK1
SCHEMBL26221013	1.00	TERT (0.55)	TERTDTYMKF2POLBTK1
SCHEMBL27103916	1.00	TERT (0.55)	TERTDTYMKF2POLBTK1
SCHEMBL26860127	1.00	TERT (0.55)	TERTDTYMKF2POLBTK1
SCHEMBL27000729	1.00	TERT (0.55)	TERTDTYMKF2POLBTK1
SCHEMBL18472071	1.00	TERT (0.55)	TERTDTYMKF2POLBTK1
SCHEMBL25456890	0.97	TERT (0.53)	TERTDTYMKF2POLBTK1
SCHEMBL18993187	0.97	TERT (0.53)	TERTDTYMKF2POLBTK1
SCHEMBL17231693	0.97	TERT (0.53)	TERTDTYMKF2POLBTK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-11873495-B2	Compounds and methods for reducing LRRK2 expression	IONIS PHARMACEUTICALS, INC. (US)	2024-01-16	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-11873495-B2	Compounds and methods for reducing LRRK2 expression	LRRK2, PARK7, SNCA	TERT 1946/4885DTYMK 1078/4885F2 4814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.